证券代码：300363 证券简称：博腾股份 重庆博腾制药科技股份有限公司 投资者关系活动记录表 编号：01120141111 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 （电话会议） | | | 参与单位名称及 | 东兴证券：宋凯、张文录 | | | 人员姓名 | 上海通晟资产管理有限公司：张烨 | | | | | 日兴资产管理香港有限公司：杜毅忠 | | 时间 | 2014 年 11 月 11 | 日 | | 地点 | 重庆博腾制药科技股份有限公司 | 1 楼会议室 | | 上市公司接待人 | | 董事会办公室工作人员：皮薇、陈靓 | | 员姓名 | 记录人: 胡鹏飞 | | | 投资者关系活动 | 投资者和 ...

Group 1: Client Development and Strategy - The company has established strategic partnerships with Johnson & Johnson and Gilead, and is currently cultivating a third major client under the "Major Client +" strategy, which also focuses on developing small and medium-sized clients [1] - In 2014, one of the top five clients was Zhangjiagang Bonded Zone Jianing Chemical Co., Ltd., a trading company that falls under the company's multi-client business [1] - Major clients typically communicate their future order intentions in advance to facilitate better collaboration [1] Group 2: Production and GMP Strategy - The company has a "3+2" layout with two production bases, one of which is located in Zhejiang Shangyu, currently in the equipment installation phase [2] - Continuous enhancement of GMP capabilities is a strategic priority to meet increasingly stringent regulatory requirements [2] - The acquisition of Jiangxi Dongbang Pharmaceutical Co., Ltd. is based on long-term cooperation and aims to extend the company's value chain and expand business scale [2] Group 3: Project and Business Classification - The company has approximately 260 projects in clinical research, but the number does not guarantee future commercialization of innovative drugs due to long development cycles and uncertainties [3] - The business is primarily focused on customized R&D production, with a portion classified as multi-client product production, which is non-customized and can be sold to various clients [3] - There is limited authoritative data on the CMO industry, particularly regarding innovative drug intermediates [3] Group 4: Regulatory and Compliance - The company received an administrative penalty in March, but it has not affected any merger and acquisition matters, and the documentation has been submitted to the regulatory authority for normal review [3]

证券代码：300363 证券简称：博腾股份 重庆博腾制药科技股份有限公司 投资者关系活动记录表 编号：00120150309 | --- | --- | --- | |-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------| | | | | | | ■特定对象调研 □分析师会议 | | | 投资者关系活动类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （电话会议） | | | 参与单位名称及人员姓名 | 方正证券：崔文亮 信达澳银基金：张培培、杜蜀鹏、曾国富 建信基金：潘龙玲 中山证券有限责任公司：黄志刚 华夏基金：刘 ...

Group 1: Company Overview and Projects - The company has disclosed 260 reserve projects in its 2014 annual report, primarily focusing on innovative drugs in clinical research stages, including areas like anti-diabetes, anti-HIV, anti-hepatitis C, and anti-tumor [1] - The 108 workshop is currently in the equipment debugging phase, while the 109 workshop has been repurposed from a GMP pilot workshop to a self-funded project due to market changes [2] - The 110 workshop has partially commenced production with a capacity of 300 cubic meters, and the 304 workshop is a multifunctional pilot workshop supporting the Chongqing R&D center [2] Group 2: Strategic Partnerships and Market Position - The company does not sign exclusive agreements with strategic partners, as supply chain management typically involves multiple suppliers [2] - One of the top five customers in 2014 was a domestic trading company, indicating a diverse customer base [2] - The company faces high industry barriers, requiring long-term relationship building with clients, which makes it difficult for clients to switch suppliers easily [3] Group 3: Competition and Market Dynamics - The main competitors are primarily international, with domestic competitors like WuXi AppTec and Kelun not directly competing due to differing service areas [3] - The CMO industry in China is still in its infancy, representing a small share of the global market, and there is a desire for the industry to grow and gain more influence internationally [3] Group 4: Financial Performance and Future Strategies - The company's performance is subject to seasonal fluctuations based on client demand, and there is no stable pattern in sales [3] - The company aims to develop a "one-stop service platform," indicating potential expansion beyond intermediates in the long term [3] - The acquisition of Jiangxi Dongbang Pharmaceutical Co., Ltd. is part of a strategic move to enhance the company's value chain and focus on GMP intermediate business [3]

证券代码：300363 证券简称：博腾股份 重庆博腾制药科技股份有限公司 投资者关系活动记录表 编号：01620151118 | --- | --- | --- | |---------------------------------------------|----------------------------------|-------------------------------------------------------------------------| | | | | | | ■特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （电话会议） | | | 参与单位名称及人员姓名 | 维，徐先生，袁先生 | 银河基金管理有限公司：钱睿南，神玉飞，罗博，王海华，李 | | | 西南证券：何治力，杨胜蓝 | | | 时间 2015 | 年 11 月 18 日 | | | | | | | 地点 重庆博腾制药科技股份有限公司五楼会议室 | | | | | | 上市公司 ...

Group 1: Financial Performance - The company's revenue growth in Q4 last year was significant, but this year's Q4 performance is sensitive information and cannot be disclosed [1] - The company's multi-client product business grew nearly twofold in the first half of this year, attributed to internal business growth rather than the acquisition of Dongbang Pharmaceutical [1] Group 2: Production Capacity - The company has approximately 600 cubic meters of commercial production capacity and about 400 cubic meters of pilot production capacity at its Changshou production base [2] - The company’s subsidiary, Zhejiang Boten, has around 180 cubic meters of pilot production capacity, while the recently acquired Jiangxi Dongbang Pharmaceutical has about 300 cubic meters of multifunctional product capacity [2] Group 3: Research and Development - The Chengdu and Chongqing R&D centers support the Chongqing production base, focusing on new product development, especially GMP products [2] - The Shanghai R&D center, which supports the Zhejiang Shangyu production base, is dedicated to early-stage non-GMP product development and FTE project development [2] Group 4: Financial Metrics - The fixed asset depreciation for the first half of this year was approximately 23 million [3] - The gross margin for innovative pharmaceutical raw materials is higher than that of intermediates, with foreign reports indicating that biological CMO gross margins are also higher [3]

证券代码：300363 证券简称：博腾股份 重庆博腾制药科技股份有限公司 投资者关系活动记录表 编号：01920151222 | --- | --- | |-----------------------------------------------------|------------------------------------------------------------------------------------| | | | | | □分析师会议 | | | □媒体采访 □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | | | （电话会议） | | 参与单位名称及人员姓名 | 中金公司：邹朋、张琎 中海基金管理有限公司：郑辰 交银施罗德基金管理有限公司：桂慧源 | | | 上投摩根基金管理有限公司：张一甫、方钰涵 | | 时间 2015 | | | 地点 重庆博腾制药科技股份有限公司五楼 | | | | | | 上市公司接待人员姓名 董事长居年丰，证券事务代表皮薇 | | | | 投资者和公司的交流内容如下： | | | 、公司未来的战略规划是怎么样的？ ...

证券代码：300363 证券简称：博腾股份 重庆博腾制药科技股份有限公司 投资者关系活动记录表 编号：02020151223 | --- | --- | --- | |------------------------|-------------------------------------|-------------------------------------------------------------------------| | | | | | | ■特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （电话会议） | | | | | 参与单位名称及人员姓名 世纪红帆（北京）资产管理有限公司：薄宗臣，于淼 | | 时间 2015 | 年 12 月 23 日 | | | 地点 | 重庆博腾制药科技股份有限公司四楼 | | | | | 上市公司接待人员姓名 董事会秘书陶荣，证券事务代表皮薇，董事会办公室陈靓 | | | 投资者和公司的交流内容如下： | | | | 1 ...

证券代码：300363 证券简称：博腾股份 重庆博腾制药科技股份有限公司 投资者关系活动记录表 编号：02120151228 | --- | --- | --- | |---------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------| | | | | | | ■特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （电话会议） | | | 参与单位名称及人员姓名 | 前方基金管理公司：粱剑文 晓扬投资管理有限公司：戴祖祥 | | | | 深圳市唐融投资有限公司：仇石石 | | | 时间 2015 | 年 12 月 28 日 | | | 地点 | 重庆博腾制药科技股份有限公司五楼 | | | 上市公 ...

证券代码：300363 证券简称：博腾股份 重庆博腾制药科技股份有限公司 投资者关系活动记录表 编号：01520151029 | --- | --- | --- | |-------------------------------------------------------------|-----------------------------------|----------------------------------------------------------| | | | | | | ■特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （电话会议） | | | | 嘉实基金：高兰君 | | | | 星石投资：方磊 | | | 参与单位名称及人员姓名 | 银华基金：魏卓 | | | | 中欧基金：龙宇飞 | | | | 兵工财务有限责任公司：邱泱 | | | 时间 2015 年 10 月 29 日 | | | | 地点 重庆博腾制药科技股份有限公司五楼会议室 | ...